Italia markets open in 52 minutes

Werewolf Therapeutics, Inc. (HOWL)

NasdaqGS - NasdaqGS Prezzo in tempo reale. Valuta in USD.
Aggiungi a watchlist
3,0100-0,2400 (-7,38%)
Alla chiusura: 04:00PM EDT
3,0100 0,00 (0,00%)
Dopo ore: 04:17PM EDT
Schermo intero
I prezzi di scambio non provengono da tutti i mercati
Chiusura precedente3,2500
Aperto3,2700
Denaro2,9900 x 400
Domanda3,0600 x 100
Min-Max giorno3,0100 - 3,2700
Intervallo di 52 settimane1,5740 - 8,1940
Volume193.562
Media Volume186.784
Capitalizzazione130,801M
Beta (mensile su 5 anni)0,62
Rapporto PE (ttm)N/D
EPS (ttm)-1,1000
Prossima data utiliN/D
Rendimento e dividendo (futuro)N/D (N/D)
Data ex dividendoN/D
Stima target 1A12,50
  • GlobeNewswire

    Werewolf Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting

    Six abstracts, spanning Werewolf’s PREDATOR™ platform and INDUKINE™ pipeline, accepted for poster presentations at SITC annual meetingCompany to present interim first-in-human clinical data from initial monotherapy dose-escalation cohorts in ongoing Phase 1/1b study of WTX-124 WATERTOWN, Mass., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated t

  • GlobeNewswire

    Werewolf Therapeutics to Host KOL Event Highlighting IL-2 Landscape and Opportunity for WTX-124

    Virtual event to be held on Monday, September 18, 2023, at 10:00 am ETWATERTOWN, Mass., Sept. 11, 2023 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer, today announced that it will host a virtual R&D Event on Monday, September 18, 2023, at 10:00 am ET. The event will fe

  • GlobeNewswire

    Werewolf Therapeutics to Participate in Upcoming Investor Conferences

    WATERTOWN, Mass., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer, today announced that management will participate in the following upcoming investor conferences in the month of September: H.C. Wainwright Annual Global Investor ConferenceDate: Monday, Se